The popularity of Sildenafil initially fueled a boom for major pharmaceutical companies, nevertheless recent developments present a uncertain picture for those considering a stake. Generic versions are eroding profits, https://neveocme651883.timeblog.net/77068311/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment